Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Half-Year Ended 31St March, 2020
With reference to above subject, please find enclosed Compliance Certificate for the half-year ended 31st March, 2020 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Suven Pharmaceuticals Ltd - 543064 - Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Suven Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed. Suven Pharmaceuticals Ltd - 543064 - Clarification sought from Suven Life Sciences Ltd
The Exchange has sought clarification from Suven Life Sciences Ltd on April 03rd, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2020 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2020, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed News Release of our company titled 'Suven COVID-19 Alert.' Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting
With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 23rd March, 2020, has taken on record and approved the following matter(s). 1) Approved among other matters, the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) and Policy on determination of legitimate purpose in pursuance to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The code is effective from March 9, 2020 and uploaded on our company's website and 2) Approved the repositioning of Suven Pharma, Inc. in USA (engaged in CRAMS related business), the wholly owned subsidiary of Suven Life Sciences Ltd to Suven Pharmaceuticals Ltd, post demerger subject to necessary approvals, if any.